This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/company/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/mixture/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04711/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB04711/identifier/pdb/
n7http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB04711/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB04711/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/drugbank/drug/DB04711/identifier/kegg-drug/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB04711/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB04711/identifier/chemspider/
n23http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04711
rdf:type
n3:Drug
n3:description
Iodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography. [PubChem]
n3:dosage
n5:271B4C17-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Lin SK, Moss AA, Riegelman S: Iodipamide kinetics: capacity-limited biliary excretion with simultaneous pseudo-first-order renal excretion. J Pharm Sci. 1977 Dec;66(12):1670-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/925927
n3:group
approved
n3:indication
Iodipamide is used as a contrast agent for cholecystography and intravenous cholangiography.
owl:sameAs
n7:DB04711 n21:DB04711
dcterms:title
Iodipamide
adms:identifier
n11:46507320 n12:PA164745532 n13:3739 n14:D01774 n15:IDB n16:3608 n20:DB04711
n3:mechanismOfAction
Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these iodinated organic compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. Iodipamide's primary excretion through the hepato-biliary system and concentration in bile allows visualization of the gallbladder and biliary ducts.
n3:packager
n17:271B4C15-363D-11E5-9242-09173F13E4C5
n3:synonym
Adipiodonum Adipiodona Iodipamide Adipiodone
n3:toxicity
Ionic radiocontrast agents like iodipamide are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress. Acute IV LD50 is 5000 mg/kg in rat, 3195 mg/kg in mouse, and 1200 mg/kg in dog.
n3:mixture
n8:271B4C14-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
U.S. Patent 2,776,241.
n18:hasConcept
n19:M0011648
n3:IUPAC-Name
n4:271B4C1C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4C22-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4C21-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4C1E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4C1F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4C20-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4C1A-363D-11E5-9242-09173F13E4C5 n4:271B4C32-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4C18-363D-11E5-9242-09173F13E4C5 n4:271B4C1B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4C19-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n23:V08AC04
n3:H-Bond-Acceptor-Count
n4:271B4C28-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4C29-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4C23-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4C24-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4C26-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4C25-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4C27-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
606-17-7
n3:category
n3:containedIn
n24:271B4C16-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4C2E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4C30-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4C31-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4C33-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4C2D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4C2C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4C2F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4C1D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4C2A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4C2B-363D-11E5-9242-09173F13E4C5